Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Laith J Abu-Raddad; Hiam Chemaitelly; Houssein H Ayoub; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Peter Coyle; Sawsan AlMukdad; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Adeel A Butt; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Roberto Bertollini

doi:10.1093/cid/ciab909

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Laith J Abu-Raddad
, Hiam Chemaitelly
, Houssein H Ayoub
, Hadi M Yassine
, Fatiha M Benslimane
, Hebah A Al Khatib
, Patrick Tang
, Mohammad R Hasan
, Peter Coyle
, Sawsan AlMukdad
, Zaina Al Kanaani
, Einas Al Kuwari
, Andrew Jeremijenko
, Anvar Hassan Kaleeckal
, Ali Nizar Latif
, Riyazuddin Mohammad Shaik
, Hanan F Abdul Rahim
, Gheyath K Nasrallah
, Mohamed Ghaith Al Kuwari
, Adeel A Butt

Hamad Eid Al Romaihi, Mohamed H Al-Thani, Abdullatif Al Khal, Roberto Bertollini

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

80 Downloads (Pure)

Abstract

Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.

Original language	English
Journal	Clinical Infectious Diseases
Early online date	17 Oct 2021
DOIs	https://doi.org/10.1093/cid/ciab909
Publication status	Early online date - 17 Oct 2021

Keywords

infection
variant
SARS-CoV-2
epidemiology
case-control
severe disease

Access to Document

10.1093/cid/ciab909Licence: CC BY-NC-ND

Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
Copyright 2021 The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited
Final published version, 870 KBLicence: CC BY-NC-ND

Cite this

Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., AlMukdad, S., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., ... Bertollini, R. (2021). Severity, criticality, and fatality of the SARS-CoV-2 Beta variant. Clinical Infectious Diseases. Advance online publication. https://doi.org/10.1093/cid/ciab909

@article{f37b652ffa4b4b059fddf35a2e815d00,

title = "Severity, criticality, and fatality of the SARS-CoV-2 Beta variant",

abstract = "Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95\% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95\% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95\% CI: 1.03-2.43) higher.",

keywords = "infection, variant, SARS-CoV-2, epidemiology, case-control, severe disease",

author = "Abu-Raddad, \{Laith J\} and Hiam Chemaitelly and Ayoub, \{Houssein H\} and Yassine, \{Hadi M\} and Benslimane, \{Fatiha M\} and \{Al Khatib\}, \{Hebah A\} and Patrick Tang and Hasan, \{Mohammad R\} and Peter Coyle and Sawsan AlMukdad and \{Al Kanaani\}, Zaina and \{Al Kuwari\}, Einas and Andrew Jeremijenko and Kaleeckal, \{Anvar Hassan\} and Latif, \{Ali Nizar\} and Shaik, \{Riyazuddin Mohammad\} and \{Abdul Rahim\}, \{Hanan F\} and Nasrallah, \{Gheyath K\} and \{Al Kuwari\}, \{Mohamed Ghaith\} and Butt, \{Adeel A\} and \{Al Romaihi\}, \{Hamad Eid\} and Al-Thani, \{Mohamed H\} and \{Al Khal\}, Abdullatif and Roberto Bertollini",

year = "2021",

month = oct,

day = "17",

doi = "10.1093/cid/ciab909",

language = "English",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

Abu-Raddad, LJ, Chemaitelly, H, Ayoub, HH, Yassine, HM, Benslimane, FM, Al Khatib, HA, Tang, P, Hasan, MR, Coyle, P, AlMukdad, S, Al Kanaani, Z, Al Kuwari, E, Jeremijenko, A, Kaleeckal, AH, Latif, AN, Shaik, RM, Abdul Rahim, HF, Nasrallah, GK, Al Kuwari, MG, Butt, AA, Al Romaihi, HE, Al-Thani, MH, Al Khal, A & Bertollini, R 2021, 'Severity, criticality, and fatality of the SARS-CoV-2 Beta variant', Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab909

TY - JOUR

T1 - Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

AU - Abu-Raddad, Laith J

AU - Chemaitelly, Hiam

AU - Ayoub, Houssein H

AU - Yassine, Hadi M

AU - Benslimane, Fatiha M

AU - Al Khatib, Hebah A

AU - Tang, Patrick

AU - Hasan, Mohammad R

AU - Coyle, Peter

AU - AlMukdad, Sawsan

AU - Al Kanaani, Zaina

AU - Al Kuwari, Einas

AU - Jeremijenko, Andrew

AU - Kaleeckal, Anvar Hassan

AU - Latif, Ali Nizar

AU - Shaik, Riyazuddin Mohammad

AU - Abdul Rahim, Hanan F

AU - Nasrallah, Gheyath K

AU - Al Kuwari, Mohamed Ghaith

AU - Butt, Adeel A

AU - Al Romaihi, Hamad Eid

AU - Al-Thani, Mohamed H

AU - Al Khal, Abdullatif

AU - Bertollini, Roberto

PY - 2021/10/17

Y1 - 2021/10/17

N2 - Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.

AB - Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to critical disease were 1.49-fold (95% CI: 1.13-1.97) higher. Odds of COVID-19 death were 1.57-fold (95% CI: 1.03-2.43) higher.

KW - infection

KW - variant

KW - SARS-CoV-2

KW - epidemiology

KW - case-control

KW - severe disease

U2 - 10.1093/cid/ciab909

DO - 10.1093/cid/ciab909

M3 - Article

C2 - 34657152

SN - 1058-4838

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Severity, criticality, and fatality of the SARS-CoV-2 Beta variant

Abstract

Keywords

Access to Document

Fingerprint

Cite this